S&P 500 rises as health care, tech gain to overshadow Fed independence concerns
Investing.com - Cantor Fitzgerald has reiterated its Overweight rating on Alumis Inc (NASDAQ:ALMS), maintaining its positive outlook despite the stock’s significant decline following its merger with Acelyrin. Currently trading at $4.42, InvestingPro data shows analyst consensus remains strongly bullish with a mean price target suggesting significant upside potential.
ALMS shares have fallen approximately 40% since the merger announcement, according to Cantor Fitzgerald analyst Eric Schmidt. The stock is down 65% over the past year, though InvestingPro analysis indicates the company maintains a healthy current ratio of 6.05, with liquid assets well exceeding short-term obligations.
Despite the price decline, Cantor Fitzgerald notes that the transaction provided Alumis with "much needed capital" to fund three large ongoing clinical studies, including two in psoriasis with data expected in the first quarter of 2026 and a Phase 2b study in systemic lupus erythematosus (SLE) with results anticipated in the third quarter of 2026.
The research firm believes Alumis is "in a much better position having consummated the transaction," citing that the company is now capitalized through its 2026 clinical readouts.
Cantor Fitzgerald also highlighted that Alumis is now six months closer to receiving data from these clinical trials, suggesting potential catalysts ahead for the pharmaceutical company.
In other recent news, Alumis Inc. has completed its merger with ACELYRIN, Inc., a strategic move that is anticipated to enhance the company’s financial standing by extending its cash runway into 2027. This merger also marks the cessation of ACELYRIN stock trading on the NASDAQ Global Select Market, with shareholders receiving Alumis stock in exchange. Guggenheim has responded to these developments by upgrading Alumis to a Buy rating, setting a price target of $18.00. The firm noted significant milestones in Alumis’s drug development, including promising 52-week data for ESK-001, a treatment for psoriasis, demonstrating notable efficacy and safety.
Additionally, Alumis has completed patient enrollment for its Phase 2b trial of ESK-001 for systemic lupus erythematosus, with results expected in the third quarter of 2026. In leadership news, Sanam Pangali has been promoted to Chief Legal Officer and Corporate Secretary, succeeding Sara Klein. Pangali will oversee legal and compliance functions, including corporate governance and intellectual property. These developments reflect Alumis’s ongoing efforts to advance its therapeutic pipeline and strengthen its organizational structure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.